Robert W. Baird Increases Quest Diagnostics (NYSE:DGX) Price Target to $255.00

Quest Diagnostics (NYSE:DGX) had its price target increased by research analysts at Robert W. Baird from $236.00 to $255.00 in a research report issued on Friday, MarketBeat.com reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price points to a potential upside of 11.82% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. Truist Financial boosted their target price on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research note on Wednesday, April 22nd. Weiss Ratings upgraded Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. UBS Group increased their target price on Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. Wall Street Zen downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Finally, Evercore set a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $231.73.

Quest Diagnostics Stock Performance

Shares of NYSE DGX opened at $228.05 on Friday. The firm’s 50-day moving average price is $203.23 and its 200-day moving average price is $197.59. Quest Diagnostics has a 52-week low of $165.78 and a 52-week high of $237.78. The company has a market cap of $25.25 billion, a PE ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58. The company has a quick ratio of 1.08, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, analysts anticipate that Quest Diagnostics will post 11.17 EPS for the current year.

Insider Buying and Selling at Quest Diagnostics

In related news, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. The trade was a 7.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Quest Diagnostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DGX. Key Financial Inc grew its position in Quest Diagnostics by 1,728.6% in the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after acquiring an additional 121 shares in the last quarter. Quattro Advisors LLC bought a new stake in Quest Diagnostics during the fourth quarter worth approximately $25,000. JFS Wealth Advisors LLC raised its position in Quest Diagnostics by 114.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares during the period. DV Equities LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter valued at approximately $27,000. Finally, Sittner & Nelson LLC bought a new stake in shares of Quest Diagnostics in the 4th quarter valued at approximately $29,000. 88.06% of the stock is owned by institutional investors.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.